Curis (CRIS +0.3%) says it's licensed from Roche (RHHBY.PK) subsidiary Genentech, exclusive,...

|By:, SA News Editor

Curis (CRIS +0.3%) says it's licensed from Roche (RHHBY.PK) subsidiary Genentech, exclusive, worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins. Additionally, the company says it's obtained $30M in secured debt financing to fund the development of its pipeline.